A multi-centre clinical trial has begun into the effectiveness of administering cryoprecipitate in trauma patients at an early stage of treatment.
The study, called CRYOSTAT-2, is a collaboration between NHS Blood and Transfusion (NHSBT), the Centre for Trauma Sciences (C4TS) and Queen Mary University of London, and will look at whether doctors should transfuse high dose cryoprecipitate to adult trauma patients with severe bleeding within 90 minutes of admission to the emergency department.
It will also establish if the process reduces death when major bleeding occurs after injury.
Many patients who lose blood due to trauma develop a clotting deficiency that can be fatal and previous studies have suggested that treating bleeding trauma patients with fibrinogen therapy stops bleeding more effectively than standard care, reduces transfusion needs and may reduce death rates.
In England, standard care is to administer the frozen blood component cryoprecipitate a number of hours after injury
However, researchers believe that the early transfusion of cryoprecipitate, which is prepared from plasma and is rich in fibrinogen, could result in more stable blood clots and a reduction of bleeding – ultimately saving lives.
They hope to recruit 1,500 patients to the trial over three years, working with every Major Trauma Centre in England as well as in addition to international sites. The first trial site opened at St George’s Hospital in Tooting, London, and up to 23 further sites are expected to open by the end of 2017.
Disclaimer: The news stories shared on this site are used as a way to inform our members and followers of updates and relevant information happening in Haematology. The BSH does not endorse the content of news items from external sources, and is not in a position to verify the findings, accuracy or the source of any studies mentioned. Any medical or drugs information is provided as an information resource only, and is not to be relied on for any diagnostic or treatment purposes.